Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2039
mi
from 98109
Huntsville, AL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2039
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
625
mi
from 98109
Carmichael, CA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
625
mi
from 98109
Carmichael, CA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
946
mi
from 98109
Northridge, CA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
946
mi
from 98109
Northridge, CA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1717
mi
from 98109
Saint Louis, MO
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1717
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1359
mi
from 98109
Omaha, NE
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1359
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis
1786
mi
from 98109
San Antonio, TX
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis
1786
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
667
mi
from 98109
Concord, CA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
667
mi
from 98109
Concord, CA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
980
mi
from 98109
Long Beach, CA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
980
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2279
mi
from 98109
Bradenton, FL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2279
mi
from 98109
Bradenton, FL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
2512
mi
from 98109
Clearwater, FL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
2512
mi
from 98109
Clearwater, FL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
2423
mi
from 98109
Charleston, SC
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
2423
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
27
mi
from 98109
Tacoma, WA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
27
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1065
mi
from 98109
Colorado Springs, CO
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1065
mi
from 98109
Colorado Springs, CO
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1706
mi
from 98109
Gurnee, IL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1706
mi
from 98109
Gurnee, IL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1888
mi
from 98109
Sugar Land, TX
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1888
mi
from 98109
Sugar Land, TX
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
6918
mi
from 98109
Caba,
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
6918
mi
from 98109
Caba,
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
669
mi
from 98109
Stockton, CA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
669
mi
from 98109
Stockton, CA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2702
mi
from 98109
Delray Beach, FL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2702
mi
from 98109
Delray Beach, FL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2712
mi
from 98109
Fort Lauderdale, FL
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2712
mi
from 98109
Fort Lauderdale, FL
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from 98109
Bogalusa, LA
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from 98109
Bogalusa, LA
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1974
mi
from 98109
Jackson, MS
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1974
mi
from 98109
Jackson, MS
Click here to add this to my saved trials
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2322
mi
from 98109
Columbia, SC
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2322
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated:  12/31/1969
Mount Sinai M.C
2402
mi
from 98109
New York, NY
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated: 12/31/1969
Mount Sinai M.C
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center
1892
mi
from 98109
Houston, TX
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated:  12/31/1969
University of Alberta Hospital
560
mi
from 98109
Edmonton,
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
Status: Enrolling
Updated: 12/31/1969
University of Alberta Hospital
560
mi
from 98109
Edmonton,
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute
976
mi
from 98109
Los Angeles, CA
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute
976
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
2005
mi
from 98109
Lexington, KY
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
University of Maryland, Baltimore
2328
mi
from 98109
Baltimore, MD
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
University of Maryland, Baltimore
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
Capital Cardiology Associates
2351
mi
from 98109
Albany, NY
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
Capital Cardiology Associates
2351
mi
from 98109
Albany, NY
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
Fairfax Radiological Consultants
2313
mi
from 98109
Fairfax, VA
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
Fairfax Radiological Consultants
2313
mi
from 98109
Fairfax, VA
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
University of Montreal Medical Center
2280
mi
from 98109
Montreal,
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
University of Montreal Medical Center
2280
mi
from 98109
Montreal,
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
George Washington University School of Medicine
2321
mi
from 98109
Washington,
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
George Washington University School of Medicine
2321
mi
from 98109
Washington,
Click here to add this to my saved trials
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated:  12/31/1969
Long Beach Veterans Affairs
982
mi
from 98109
Long Beach, CA
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)
Status: Enrolling
Updated: 12/31/1969
Long Beach Veterans Affairs
982
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Anticoagulation Medical Home
Anticoagulation Medical Home for High-Risk Patients With Venous Thromboembolism: Patient Education, Anticoagulant Decision-Making, and Patient Self-Efficacy in the Home Coordinated by the UMass Anticoagulation Team
Status: Enrolling
Updated:  12/31/1969
UMass Medical School
2456
mi
from 98109
Worcester, MA
Anticoagulation Medical Home
Anticoagulation Medical Home for High-Risk Patients With Venous Thromboembolism: Patient Education, Anticoagulant Decision-Making, and Patient Self-Efficacy in the Home Coordinated by the UMass Anticoagulation Team
Status: Enrolling
Updated: 12/31/1969
UMass Medical School
2456
mi
from 98109
Worcester, MA
Click here to add this to my saved trials
Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.
The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.
The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
The Computed Tomography-derived Fractional Flow Reserve STAT Trial
Computed Tomography-derived Fractional Flow Reserve in the Systematic Triage of Emergency Department Acute Chest Pain Patients to Treatment. (The CTFFR-STAT Trial)
Status: Enrolling
Updated:  12/31/1969
Beaumont Health System - Royal Oak
1922
mi
from 98109
Royal Oak, MI
The Computed Tomography-derived Fractional Flow Reserve STAT Trial
Computed Tomography-derived Fractional Flow Reserve in the Systematic Triage of Emergency Department Acute Chest Pain Patients to Treatment. (The CTFFR-STAT Trial)
Status: Enrolling
Updated: 12/31/1969
Beaumont Health System - Royal Oak
1922
mi
from 98109
Royal Oak, MI
Click here to add this to my saved trials
HCR vs. CABG Study
Hybrid Coronary Revascularization Versus Coronary Artery Bypass Surgery for Treatment of Multivessel Coronary Disease
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
2178
mi
from 98109
Atlanta, GA
HCR vs. CABG Study
Hybrid Coronary Revascularization Versus Coronary Artery Bypass Surgery for Treatment of Multivessel Coronary Disease
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access
The OHIO Trial: A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access
Status: Enrolling
Updated:  12/31/1969
Ohio State University
2006
mi
from 98109
Columbus, OH
A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access
The OHIO Trial: A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access
Status: Enrolling
Updated: 12/31/1969
Ohio State University
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
Status: Enrolling
Updated:  12/31/1969
West Coast Clinical Trials
981
mi
from 98109
Anaheim, CA
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
Status: Enrolling
Updated: 12/31/1969
West Coast Clinical Trials
981
mi
from 98109
Anaheim, CA
Click here to add this to my saved trials
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated:  12/31/1969
Hillsborough Fire Rescue
2531
mi
from 98109
Tampa, FL
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated: 12/31/1969
Hillsborough Fire Rescue
2531
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated:  12/31/1969
Houston Fire
1890
mi
from 98109
Houston, TX
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated: 12/31/1969
Houston Fire
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated:  12/31/1969
Gold Cross EMS
1633
mi
from 98109
Menasha, WI
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated: 12/31/1969
Gold Cross EMS
1633
mi
from 98109
Menasha, WI
Click here to add this to my saved trials
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated:  12/31/1969
Vienna EMS
5367
mi
from 98109
Vienna,
Circulation Improving Resuscitation Care (CIRC)
A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest
Status: Enrolling
Updated: 12/31/1969
Vienna EMS
5367
mi
from 98109
Vienna,
Click here to add this to my saved trials
Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI
Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in Percutaneous Coronary Intervention (PCI)
Status: Enrolling
Updated:  12/31/1969
Columbia University
2400
mi
from 98109
New York, NY
Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI
Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in Percutaneous Coronary Intervention (PCI)
Status: Enrolling
Updated: 12/31/1969
Columbia University
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 2-Part Study to Assess the Safety, Tolerability and Pharmacokinetic Response and Explore the Pharmacodynamic Response Following 4 Weeks of Once Weekly Subcutaneous Injections of PB1046 in Adult Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF) (Part 1) and in Subjects With Cardiac Dysfunction Secondary to Duchenne Muscular Dystrophy (Part 2)
Status: Enrolling
Updated:  12/31/1969
Pinnacle Research Group, LLC
2121
mi
from 98109
Anniston, AL
Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 2-Part Study to Assess the Safety, Tolerability and Pharmacokinetic Response and Explore the Pharmacodynamic Response Following 4 Weeks of Once Weekly Subcutaneous Injections of PB1046 in Adult Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF) (Part 1) and in Subjects With Cardiac Dysfunction Secondary to Duchenne Muscular Dystrophy (Part 2)
Status: Enrolling
Updated: 12/31/1969
Pinnacle Research Group, LLC
2121
mi
from 98109
Anniston, AL
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 2-Part Study to Assess the Safety, Tolerability and Pharmacokinetic Response and Explore the Pharmacodynamic Response Following 4 Weeks of Once Weekly Subcutaneous Injections of PB1046 in Adult Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF) (Part 1) and in Subjects With Cardiac Dysfunction Secondary to Duchenne Muscular Dystrophy (Part 2)
Status: Enrolling
Updated:  12/31/1969
Phoenix Medical Research, Inc.
1104
mi
from 98109
Peoria, AZ
Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 2-Part Study to Assess the Safety, Tolerability and Pharmacokinetic Response and Explore the Pharmacodynamic Response Following 4 Weeks of Once Weekly Subcutaneous Injections of PB1046 in Adult Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF) (Part 1) and in Subjects With Cardiac Dysfunction Secondary to Duchenne Muscular Dystrophy (Part 2)
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research, Inc.
1104
mi
from 98109
Peoria, AZ
Click here to add this to my saved trials